CLBS-14

N/A

Report date: 2023/01/12 15:52:08

Base Information

Drug NameCLBS-14
Drug Alias NameCLBS14-RfACD34+ cell therapy (Caladrius Biosciences/Cedars-Sinai Medical Center)CLBS14-CMDCLBS14-NORDACLBS-16 +[6] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronary Artery DiseaseCoronary DiseaseAngina Pectoris +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCaladrius Biosciences IncCedars-Sinai Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesCedars-Sinai Medical CenterCaladrius Biosciences Inc
Inactive CompaniesLisata Therapeutics Inc
Active IndicationsAngina Pectoris
Inactive IndicationsCoronary Artery DiseaseCoronary DiseaseEsophageal Stenosis

Other Information

ATC CodeN/A
Related LinksN/A